公开(公告)号：US20160250395A1

公开(公告)日：2016-09-01

申请号：US15028803

申请日：2014-09-10

Applicant: ONO PHARMACEUTICAL CO., LTD. ,  OSAKA UNIVERSITY

Inventor： Yoshiki Sawa ,  Toru Kuratani ,  Koichi Toda ,  Takayoshi Ueno ,  Shigeru Miyagawa ,  Satsuki Fukushima ,  Atsuhiro Saito ,  Yoshiki Watanabe ,  Yoshiki Sakai

IPC: A61L31/16 ,  A61F2/07 ,  A61L31/14 ,  A61F2/82

CPC classification number: A61L31/16 ,  A61F2/07 ,  A61F2/82 ,  A61F2240/001 ,  A61F2250/0067 ,  A61F2310/0097 ,  A61K9/0024 ,  A61K31/343 ,  A61K31/4406 ,  A61K31/5585 ,  A61K47/34 ,  A61K47/36 ,  A61K47/42 ,  A61L31/148 ,  A61L2300/412 ,  A61L2300/602

Abstract: The present invention provides a drug-eluting stent graft for preventing stent graft-related complications as well as treating aneurysm. Specifically, the present invention relates to a drug-eluting stent graft comprising a drug, a drug-retaining agent and a stent graft, and a method for therapy of aneurysm including the use of the drug-eluting stent graft.

Abstract translation: 本发明提供了用于预防支架移植物相关并发症以及治疗动脉瘤的药物洗脱支架移植物。 具体而言，本发明涉及包含药物，药物保留剂和支架移植物的药物洗脱支架移植物，以及包括使用药物洗脱支架移植物的动脉瘤治疗方法。

公开(公告)号：US09597436B2

公开(公告)日：2017-03-21

申请号：US14429565

申请日：2013-09-13

Applicant: Osaka University ,  Nipro Corporation ,  Ono Pharmaceutical Co., Ltd.

Inventor： Yoshiki Sawa ,  Shigeru Miyagawa ,  Satsuki Fukushima ,  Atsuhiro Saito ,  Yoshiki Sakai ,  Kazuhisa Matsuda ,  Takayuki Maruyama

IPC: A61K31/16 ,  A61K31/4406 ,  A61K31/343 ,  A61K9/16 ,  A61K9/00 ,  A61L31/14 ,  A61L31/16

CPC classification number: A61L31/16 ,  A61F2/2481 ,  A61K9/0024 ,  A61K9/16 ,  A61K9/1647 ,  A61K31/343 ,  A61K31/4406 ,  A61K47/42 ,  A61L17/005 ,  A61L17/12 ,  A61L17/145 ,  A61L31/06 ,  A61L31/10 ,  A61L31/146 ,  A61L31/148 ,  A61L2300/412 ,  A61L2300/622 ,  A61L2430/20 ,  C08L89/00 ,  C08L89/06 ,  C08L67/04

Abstract: Provided is an advanced heart failure treatment material, as a myocardial/cardiovascular regeneration device, that self-assembles, which can improve the universality and be used in an emergency by commercialization with no need of cell-culturing (cell-free) by controlling stem cells, and has a high therapeutic effect on the fundamental treatment of intractable cardiovascular diseases, in particular, advanced heart failure, in which not only the saving of lives but also improving the patient's quality of life (QOL) are urgent issues. The advanced heart failure treatment material includes a pharmaceutical agent, an agent holding for the pharmaceutical agent, and a myocardial support device.

公开(公告)号：US20150231312A1

公开(公告)日：2015-08-20

申请号：US14429565

申请日：2013-09-13

Applicant: Osaka University ,  Nipro Corporation ,  Ono Pharmaceutical Co., Ltd.

Inventor： Yoshiki Sawa ,  Shigeru Miyagawa ,  Satsuki Fukushima ,  Atsuhiro Saito ,  Yoshiki Sakai ,  Kazuhisa Matsuda ,  Takayuki Maruyama

IPC: A61L31/16 ,  A61L31/14 ,  A61K9/00 ,  A61K9/16 ,  A61K31/4406 ,  A61K31/343

CPC classification number: A61L31/16 ,  A61F2/2481 ,  A61K9/0024 ,  A61K9/16 ,  A61K9/1647 ,  A61K31/343 ,  A61K31/4406 ,  A61K47/42 ,  A61L17/005 ,  A61L17/12 ,  A61L17/145 ,  A61L31/06 ,  A61L31/10 ,  A61L31/146 ,  A61L31/148 ,  A61L2300/412 ,  A61L2300/622 ,  A61L2430/20 ,  C08L89/00 ,  C08L89/06 ,  C08L67/04

Abstract: Provided is an advanced heart failure treatment material, as a myocardial/cardiovascular regeneration device, that self-assembles, which can improve the universality and be used in an emergency by commercialization with no need of cell-culturing (cell-free) by controlling stem cells, and has a high therapeutic effect on the fundamental treatment of intractable cardiovascular diseases, in particular, advanced heart failure, in which not only the saving of lives but also improving the patient's quality of life (QOL) are urgent issues. The advanced heart failure treatment material includes a pharmaceutical agent, an agent holding for the pharmaceutical agent, and a myocardial support device.

Abstract translation: 提供了一种先进的心力衰竭治疗材料，作为心肌/心血管再生装置，可自我组装，可以通过商业化提高普遍性并在紧急情况下使用，无需细胞培养（无细胞），通过控制茎 对于顽固性心血管疾病，特别是晚期心力衰竭的基础治疗具有很高的治疗效果，其中不仅挽救生命，而且改善患者的生活质量（QOL）是迫切的问题。 先进的心力衰竭治疗材料包括药剂，用于药剂的药剂和心肌支持装置。

公开(公告)号：US09968716B2

公开(公告)日：2018-05-15

申请号：US15028803

申请日：2014-09-10

Applicant: Ono Pharmaceutical Co., Ltd. ,  Osaka University

Inventor： Yoshiki Sawa ,  Toru Kuratani ,  Koichi Toda ,  Takayoshi Ueno ,  Shigeru Miyagawa ,  Satsuki Fukushima ,  Atsuhiro Saito ,  Yoshiki Watanabe ,  Yoshiki Sakai

IPC: A61L31/16 ,  A61F2/07 ,  A61L31/14 ,  A61F2/82 ,  A61K47/34 ,  A61K47/36 ,  A61K47/42 ,  A61K31/343 ,  A61K31/4406 ,  A61K31/5585 ,  A61K9/00

CPC classification number: A61L31/16 ,  A61F2/07 ,  A61F2/82 ,  A61F2240/001 ,  A61F2250/0067 ,  A61F2310/0097 ,  A61K9/0024 ,  A61K31/343 ,  A61K31/4406 ,  A61K31/5585 ,  A61K47/34 ,  A61K47/36 ,  A61K47/42 ,  A61L31/148 ,  A61L2300/412 ,  A61L2300/602

Abstract: The present invention provides a drug-eluting stent graft for preventing stent graft-related complications as well as treating aneurysm. Specifically, the present invention relates to a drug-eluting stent graft comprising a drug, a drug-retaining agent and a stent graft, and a method for therapy of aneurysm including the use of the drug-eluting stent graft.

公开(公告)号：US08642630B2

公开(公告)日：2014-02-04

申请号：US13856538

申请日：2013-04-04

Applicant: Ono Pharmaceutical Co., Ltd.

Inventor： Yoshiki Sakai ,  Akio Nishiura ,  Teppei Ogata

IPC: A61K31/04

CPC classification number: A61K31/4406 ,  A61K9/1647 ,  A61K9/5031 ,  A61K31/19 ,  A61K31/343 ,  A61K31/403 ,  A61K45/06

Abstract: It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) I2 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) I2 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and/or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases.

Abstract translation: 它涉及内源性修复因子产生促进剂，其包含选自前列腺素（PG）I2激动剂，EP2激动剂和EP4激动剂中的一种或至少两种。 由于前列腺素（PG）I2激动剂，EP2激动剂或EP4激动剂具有各种内源性修复因子产生促进作用，血管生成加速作用和干细胞分化诱导作用，其可用作缺血性器官疾病（例如动脉硬化症）的预防和/或治疗剂 闭塞性心脏病，勃起病，雷诺病，心肌梗死，心绞痛，糖尿病性神经病变，椎管狭窄，脑血管意外，脑梗死，肺动脉高压，骨折，阿尔茨海默病等）和各种细胞和器官疾病。

公开(公告)号：US20210113464A1

公开(公告)日：2021-04-22

申请号：US16766992

申请日：2017-11-27

Applicant: Osaka University ,  Cardio Incorporated

Inventor： Yoshiki Sawa ,  Shigeru Miyagawa ,  Yoshiki Sakai ,  Yasuhiro Yanagi

IPC: A61K9/127 ,  A61K31/4406

Abstract: The present invention provides a clinically applicable, safe and convenient, pharmaceutical composition for disease site-specific treatment. The pharmaceutical composition for disease site-specific treatment comprises a stealth liposome having a prostaglandin I2 receptor agonist encapsulated therein.

公开(公告)号：US20240082154A1

公开(公告)日：2024-03-14

申请号：US18491953

申请日：2023-10-23

Applicant: Osaka University ,  Cuorips Inc

Inventor： Yoshiki Sawa ,  Shigeru Miyagawa ,  Yoshiki Sakai ,  Yasuhiro Yanagi

IPC: A61K9/127 ,  A61K31/4406

CPC classification number: A61K9/127 ,  A61K9/1277 ,  A61K31/4406

Abstract: The present invention provides clinically applicable, safe and convenient, pharmaceutical compositions and methods for disease site-specific treatment. The pharmaceutical composition for disease site-specific treatment methods comprises a stealth liposome having a prostaglandin I2 receptor agonist encapsulated therein.